Literature DB >> 17392178

Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia.

Charles J Lockwood1, Paolo Toti, Felice Arcuri, Errol Norwitz, Edmund F Funai, Se-Te J Huang, Lynn F Buchwalder, Graciela Krikun, Frederick Schatz.   

Abstract

The primary placental defect in preeclampsia is shallow trophoblast invasion of the decidua leading to incomplete vascular transformation and inadequate uteroplacental perfusion. Soluble fms-like tyrosine kinase-1 (sFlt-1) seems to interfere with these events by inhibiting local angiogenesis and/or by impeding trophoblast invasion. Preeclampsia is also associated with maternal thrombophilias and decidual hemorrhage, which form thrombin from decidual cell-expressed tissue factor. Although sFlt-1 is highly expressed by trophoblasts, sFlt-1 expression has not been studied in decidual cells, which are the predominant cell type encountered by invading trophoblasts. Here, we demonstrate that isolated decidual cells express sFlt-1 mRNA, suggesting that they can synthesize sFlt-1. Moreover, in first trimester decidual cells, thrombin enhanced sFlt-1 mRNA levels, as measured by quantitative reverse transcriptase-polymerase chain reaction, and levels of secreted sFlt-1 protein, as measured by enzyme-linked immunosorbent assay. The thrombin antagonist hirudin blocked this effect, demonstrating that active thrombin is required. Emphasizing the specificity of the thrombin response, neither interleukin-1beta nor tumor necrosis factor-alpha affected sFlt-1 expression in the decidual cells. In contrast to first trimester decidual cells, thrombin did not affect sFlt-1 levels in cultured term decidual cells. In early pregnancy, thrombin may act as an autocrine/paracrine enhancer of sFlt-1 expression by decidual cells to promote pre-eclampsia by interfering with local vascular transformation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392178      PMCID: PMC1829472          DOI: 10.2353/ajpath.2007.060465

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

1.  First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.

Authors:  Ravi Thadhani; Walter P Mutter; Myles Wolf; Richard J Levine; Robert N Taylor; Vikas P Sukhatme; Jeffrey Ecker; S Ananth Karumanchi
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

2.  Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?

Authors:  Y Zhou; C H Damsky; S J Fisher
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

3.  Progesterone metabolism in human endometrial stromal and gland cells in culture.

Authors:  A Arici; P B Marshburn; P C MacDonald; R A Dombrowski
Journal:  Steroids       Date:  1999-08       Impact factor: 2.668

4.  Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Yeon Mee Kim; Gi Jin Kim; Mi Ran Kim; Jimmy Espinoza; Emmanuel Bujold; Luís Gonçalves; Ricardo Gomez; Samuel Edwin; Moshe Mazor
Journal:  J Matern Fetal Neonatal Med       Date:  2005-01

5.  Molecular evidence of placental hypoxia in preeclampsia.

Authors:  Nima Soleymanlou; Igor Jurisica; Ori Nevo; Francesca Ietta; Xin Zhang; Stacy Zamudio; Martin Post; Isabella Caniggia
Journal:  J Clin Endocrinol Metab       Date:  2005-04-19       Impact factor: 5.958

6.  Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia.

Authors:  B K Rinehart; D A Terrone; S Lagoo-Deenadayalan; W H Barber; E A Hale; J N Martin; W A Bennett
Journal:  Am J Obstet Gynecol       Date:  1999-10       Impact factor: 8.661

7.  Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies.

Authors:  Myles Wolf; Anand Shah; Chun Lam; Abelardo Martinez; Karen V Smirnakis; Franklin H Epstein; Robert N Taylor; Jeffrey L Ecker; S Ananth Karumanchi; Ravi Thadhani
Journal:  Am J Obstet Gynecol       Date:  2005-07       Impact factor: 8.661

8.  Genetic thrombophilias and preeclampsia: a meta-analysis.

Authors:  Julie Lin; Phyllis August
Journal:  Obstet Gynecol       Date:  2005-01       Impact factor: 7.661

9.  Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia.

Authors:  Catalin S Buhimschi; Errol R Norwitz; Edmund Funai; Susan Richman; Seth Guller; Charles J Lockwood; Irina A Buhimschi
Journal:  Am J Obstet Gynecol       Date:  2005-03       Impact factor: 8.661

10.  Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance.

Authors:  Myles Wolf; Carl A Hubel; Chun Lam; Marybeth Sampson; Jeffrey L Ecker; Roberta B Ness; Augustine Rajakumar; Ashi Daftary; Alia S M Shakir; Ellen W Seely; James M Roberts; Vikas P Sukhatme; S Ananth Karumanchi; Ravi Thadhani
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

View more
  14 in total

1.  Surfactant protein-A (SP-A) selectively inhibits prostaglandin F2alpha (PGF2alpha) production in term decidua: implications for the onset of labor.

Authors:  Victoria V Snegovskikh; Vineet Bhandari; Jo Rae Wright; Serkalem Tadesse; Thomas Morgan; Colin Macneill; Nastaran Foyouzi; Joong Shin Park; Yuguang Wang; Errol R Norwitz
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

Review 2.  The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding.

Authors:  Frederick Schatz; Ozlem Guzeloglu-Kayisli; Sefa Arlier; Umit A Kayisli; Charles J Lockwood
Journal:  Hum Reprod Update       Date:  2016-02-23       Impact factor: 15.610

Review 3.  Novel insights into molecular mechanisms of abruption-induced preterm birth.

Authors:  Catalin S Buhimschi; Frederik Schatz; Graciela Krikun; Irina A Buhimschi; Charles J Lockwood
Journal:  Expert Rev Mol Med       Date:  2010-11-01       Impact factor: 5.600

Review 4.  Innate immunity, decidual cells, and preeclampsia.

Authors:  Chang-Ching Yeh; Kuan-Chong Chao; S Joseph Huang
Journal:  Reprod Sci       Date:  2012-07-18       Impact factor: 3.060

5.  Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia.

Authors:  Charles J Lockwood; S J Huang; Graciela Krikun; Rebeca Caze; Mizanur Rahman; Lynn F Buchwalder; Frederick Schatz
Journal:  Semin Thromb Hemost       Date:  2011-03-02       Impact factor: 4.180

6.  Midpregnancy levels of angiogenic markers in relation to maternal characteristics.

Authors:  Renée S Mijal; Claudia B Holzman; Sarosh Rana; S Ananth Karumanchi; Jianling Wang; Alla Sikorskii
Journal:  Am J Obstet Gynecol       Date:  2010-12-10       Impact factor: 8.661

7.  Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury.

Authors:  Patricia Redecha; Nico van Rooijen; Donald Torry; Guillermina Girardi
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

Review 8.  Pre-eclampsia part 1: current understanding of its pathophysiology.

Authors:  Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Lami Yeo; Roberto Romero
Journal:  Nat Rev Nephrol       Date:  2014-07-08       Impact factor: 28.314

9.  Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women.

Authors:  A Rajakumar; R W Powers; C A Hubel; E Shibata; F von Versen-Höynck; D Plymire; A Jeyabalan
Journal:  Placenta       Date:  2008-11-17       Impact factor: 3.481

10.  Proteases Activate Pregnancy Neutrophils by a Protease-Activated Receptor 1 Pathway: Epigenetic Implications for Preeclampsia.

Authors:  Scott W Walsh; William H Nugent; Marwah Al Dulaimi; Sonya L Washington; Phoebe Dacha; Jerome F Strauss
Journal:  Reprod Sci       Date:  2020-06-15       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.